NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
Clinical Trials
9 trialsNCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04482244 2025-07-29
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04754399 2025-05-09
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04447846 2023-05-25
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT02544763 2022-09-28
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT02544750 2022-07-14
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Jazz Pharmaceuticals
Phase 3 Completed
NCT02332655 2022-03-02
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 1/2 Completed